Application of luteolin

A technology of luteolin and medicine, applied in the field of medicine, can solve problems such as neuroinflammation not seen in luteolin, and achieve the effect of inhibiting the activity of neuroinflammation

Inactive Publication Date: 2019-11-29
GUANGDONG UNIV OF TECH
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the use of luteolin in the prevention and treatment of neuroinflammation-related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of luteolin
  • Application of luteolin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] In this example, the MTT method was used to investigate the effect of different concentrations of luteolin on the viability of mouse microglia.

[0028] (1) Cultivation of mouse microglia cell line BV-2

[0029] The cell culture medium is based on DMEM and is configured with 10% FBS and 1% double antibodies (penicillin and streptomycin). Mouse microglia cell line BV-2 cultured in 5% CO 2 , In a cell incubator at 37°C, observe the growth of the cells regularly under a microscope. When the cell adhesion area is about 70%-80% of the culture flask, trypsinize the cells and pass them down, and then continue the culture.

[0030] (2) Cell viability determination

[0031] Experimental principle: The succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystal formazan (Formazan) and deposit it in the cells, while dead cells have no such function. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and its light abso...

Embodiment 2

[0035] In this example, the Criess colorimetric method was used to investigate the inhibitory effect of luteolin on the release of NO from microglia induced by LPS;

[0036] Cell line: mouse microglia cell line BV-2;

[0037] Medicine: luteolin, LPS, NO kit

[0038] Determination of nitrite content:

[0039] Experimental principle: When LPS stimulates the body to produce neuroinflammation, BV2 cells are activated in a large amount, the expression of NOS increases rapidly, and a large amount of NO is generated; NO can induce ROS reaction to form peroxynitrite anion (ONOO-), producing neurotoxic substances OH·, OH-, cause protein degeneration and neuron damage. NO is easily oxidized to produce NO in organisms and aqueous solutions 2- And NO 3- , And NO 3- Can be reduced to NO by cadmium 2- ; NO 2- In an alkaline environment, it can react with sulfonamides to generate diazonium compounds, and then couple with N-1-naphthylethylenediamine salt. The resulting azo compounds are purple-red, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, in particular to application of luteolin. The invention discloses application of the luteolin in preparation of a drug for inhibiting microglia activation. The experiment results show that the luteolin can inhibit activation of microglia induced by LPS, and significantly inhibit production of NO signaling molecules in microglia and expression of the microglia and inflammatory factors IL-1beta, IL-6 and TNF-alpha at the downstream of a TLR4 signaling pathway. Therefore, the luteolin can remarkably inhibit neuroinflammatory activity, canbe used for preparing drugs for preventing or treating neurodegenerative diseases, and has clinical application value and development prospect.

Description

Technical field [0001] The present invention relates to the field of medical technology, in particular to the application of luteolin. Background technique [0002] NDDS (Neurodegenerative diseases, neurodegenerative diseases) is a type of neuronal disease, caused by abnormal protein accumulation and neuronal death caused by the progressive defects of neuronal structure and function in specific areas of brain tissue, including Alzheimer's disease AD), Parkinson's disease (PD), multiple sclerosis (MS), etc. At present, NDDs mostly occur in the middle-aged and elderly people. With the increasing aging of our society, this type of disease seriously affects the daily work, study and life of the middle-aged and elderly people, and also causes heavy psychological stress on the patients themselves, their families and the society. And financial burden. Due to the complex pathogenesis of ND and the special location, effective therapeutic drugs are still lacking so far. Therefore, the de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P25/00A61P25/28A61P25/16
CPCA61K31/352A61P25/00A61P25/16A61P25/28
Inventor 周渭胡蒙蒙刘起发藏小豪李尤胡锦荣
Owner GUANGDONG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap